# EP0062

Source: https://onco.cc/drugs/ep0062/  
OnCo record `ep0062` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EP0062 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at Androgen receptor.

## Summary

EP0062 is a small-molecule drug developed by Ellipses Pharma. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: EP0062 is an orally administered investigational selective androgen receptor modulator (SARM). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT05573126, plans to enrol 95 participants with primary completion expected 2028-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Small-molecule drug directed at Androgen receptor, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of EP0062: https://clinicaltrials.gov/search?intr=EP0062
- Sponsor page: https://www.ellipses.life

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [Ellipses Pharma](https://onco.cc/companies/ellipses-pharma/)
- trials: [Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer](https://onco.cc/trials/nct05573126/)

---
JSON: https://onco.cc/api/v1/entities/ep0062.json